Skip to main content
Premium Trial:

Request an Annual Quote

Money Rollin’ In

Premium Daily


Money Rollin’ In


Lion Bioscience could receive up to $11 million in a six-year licensing deal signed with Schering for its DiscoveryCenter software. The deal includes an up-front fee of about $3 million to $5 million, as well as an estimated $100,000 to $1 million in professional services and consulting fees per year. Schering, however, has the option to cancel the agreement after three years.


Find “New Schering Deal Could Net Lion Up to $11 Million” by searching: Schering


RNAi Rising


Layoffs? Downturn? What are you talking about? At the RNAi 2003 conference in Waltham, Mass., it might as well be 1999. Nearly 200 people have shown up for this one-track, two-day event off I-95, which was organized not by a major conference company but by a former PerkinElmer scientist, Krishnarao Appasani. The talks veered toward a consensus that there is real promise that this technology will deliver.


Find “RNAi Draws a Crowd to Waltham: Optimism Abounds” by searching: Waltham Weekly


DIY Pays Off


“It was not just a fortuitous coincidence that we happened to have an array that could do this. We’ve been planning for this.”

— Joe DeRisi, University of California, San Francisco, describing how his lab used its homebrew microarray to detect coronavirus in SARS patient samples from the CDC


Find “UCSF’s Joe DeRisi on Microarrays in the Hunt for the SARS Virus” by searching: DeRisi Weekly


Look at the Big Picture


“Our job as CEOs is to step in and paint a picture for the client of what we can achieve for them, and then get them to pay for the vision. If they’re paying for the technology, we’re going to go out of business.”

— Richard Gill, AnVil CEO


Find “Executive Roundtable: Is Clinical Genomics the Cure for ‘Not Invented Here’ Syndrome?” by searching: Gill Weekly


Stars of SARS


As researchers drew worldwide attention for draft sequences of the severe acute respiratory syndrome coronavirus genome, proteomics researchers were quietly working their end of the SARS problem. John Wilkins, Kenneth Standing, and their colleagues sequenced two of the coronavirus proteins by mass spectrometry. One appears to be recognized by the immune system and could potentially become the starting point for a vaccine.


Find “University of Manitoba Proteomics Researchers Tackle SARS Virus Proteins” by searching: SARS Weekly


Us, Paranoid? Puh-leez


Will the pharmaceutical industry respond to overtures by Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, to put their squabble-laced history behind them and infuse some ‘trust’ into both parties’ pharmacogenomics initiative? Some say pharma must first put its “paranoia” behind it.


Find “Trying to Rally PGx, CDER’s Woodcock Solicits ‘Trust’ Between Pharma, FDA” by searching: CDER


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.